Diabetes Remission Increased With Dapagliflozin Plus Calorie Restriction
By Elana Gotkine HealthDay Reporter
MONDAY, Jan. 27, 2025 -- For patients with overweight or obesity and type 2 diabetes, dapagliflozin plus regular calorie restriction is associated with a significantly higher rate of remission of diabetes compared with calorie restriction alone, according to a study published online Jan. 22 in The BMJ.
Yuejun Liu, from Fudan University in Shanghai, and colleagues conducted a multicenter, double-blind randomized trial in 16 centers in China from June 12, 2020, to Jan. 31, 2023, involving 328 patients with type 2 diabetes aged 20 to 70 years, with body mass index >25 kg/m2 and diabetes duration of less than six years. Patients were randomly assigned to calorie restriction with dapagliflozin 10 mg/day or placebo.
The researchers found that diabetes remission was achieved in 44 and 28 percent of patients in the dapagliflozin and placebo groups, respectively, over 12 months (risk ratio, 1.56), meeting the predefined primary end point. Significantly greater changes in body weight (difference, −1.3 kg) and homoeostasis model assessment of insulin resistance (difference, −0.8) were seen in the dapagliflozin versus placebo group. Likewise, compared with the placebo group, significantly more improvement was seen in body fat, systolic blood pressure, and metabolic risk factors in the dapagliflozin group. The occurrence of adverse events did not differ between the groups.
"Our findings provide an alternative and more practical strategy than intensive weight management to achieve remission for patients with early type 2 diabetes," the authors write.
The study was partially funded by AstraZeneca, the manufacturer of dapagliflozin.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Canagliflozin Tied to Reduction in HbA1c in Children, Teens With T2DM
WEDNESDAY, Aug. 6, 2025 -- Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus...
GLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic Neuropathy
TUESDAY, Aug. 5, 2025 -- For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic...
Less Processed Diet May Be More Beneficial for Weight Loss
TUESDAY, Aug. 5, 2025 -- Diets high in ultra-processed food (UPF), even those meeting national dietary guidelines, may be less effective for weight loss than minimally processed...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.